secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002655
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx reports preliminary 2023 revenue $430-435M; guides 2024 revenue $500-530M
--------------------------------------------------------------------------------

- Preliminary 2023 total revenue $430-435M; Crysvita $325-330M, Dojolvi $70-71M.
- 2024 total revenue guidance $500-530M; Crysvita $375-400M, Dojolvi $75-80M.
- Year-end 2023 cash ~$776M; 2024 net cash used in ops guided <$400M.
- Phase 3 data readouts expected H1 2024 for GSDIa gene therapy (DTX401) and OI study enrollment completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/rare-20240107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer